Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 269

Phase II trial of molecularly determined treatment of children and ...

Scientific Merit: The prognosis of diffuse intrinsic pontine gliomas (DIPGs) has not improved significantly over the last 40 years.  A major reason for this limitation is the lack of an understanding of the underlying biology of these tumors, as well as the absence of appropriate targets for therapeutic intervention.  ...

targeted therapy and stem cell therapy for DIPG

BACKGROUND: Diffuse intrinsic pontine glioma (DIPG) is the leading cause of brain cancer associated deaths in children despite constituting only 10-15% of childhood brain tumours.  Approximately 300 children per year with a median age of 6-7 years will be diagnosed with DIPG in the US [about 20 per year in Australia]. &...

PRE-CLINICAL DEVELOPMENT OF NOVEL DIPG RADIOSENSITIZERS

Hypothesis: Diffuse intrinsic pontine glioma (DIPG) is a devastating disease with an almost universally fatal prognosis. Despite many clinical trials testing numerous chemotherapies and targeted systemic agents, both concurrent with RT and in the adjuvant setting, these therapies have not changed OS. We and others believe that 3 major issues contribute ...

Fenretinide, a novel agent targeting RTK/PI3K/AKT network ...

Diffuse Intrinsic Pontine Gliomas (DIPG) are the most aggressive of all childhood cancers.  They are a type of brain tumour that peak in incidence at 5-7 years of age and are the most common form of malignant glioma to affect children.  There are absolutely no effective treatments and ...

Liquid biopses for the monitoring of diffuse intrinsic pontine glioma

Diffuse intrinsic pontine glioma (DIPG) is a highly aggressive tumor of the brain stem with the worst prognosis of any newly diagnosed childhood cancer. Until recently, the development  of novel therapies was hampered by the limited understanding of the underlying genetic and biochemical abnormalities associated with this disease. However, ...

T-cell therapy for DIPG

Diffuse Intrinsic Pontine Glioma (DIPG) is a rare but incurable cancer of childhood with a pressing need for novel therapeutic strategies. Cell-based immunotherapy provides a radically new approach. Here, patient derived T-cells are grafted with the required specificity so that they can bear their destructive potential on tumour cells while ...